Acipimox

Active ingredient description

Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Acipimox
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AD Nicotinic acid and derivatives
Discover more medicines within C10AD06

Medicines

Acipimox is the active ingredient of these drugs:

Drug
Countries

Netherlands

Netherlands Singapore United Kingdom

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

K9AY9IR2SD - ACIPIMOX

CAS registry number

51037-30-0 - acipimox

SNOMED-CT

391711008 - Acipimox (substance)